Sign Out
Oxaliplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.
Aluminium has been reported to cause degradation of platinum compounds and hence needles or intravenous administration sets containing aluminium parts that may come in contact with oxaliplatin should not be used for the preparation or mixing of the drug.
Oxaliplatin should not be administered undiluted. Dilute with 5% Dextrose infusion.
Oxaliplatin should not be mixed with any other medication and it should not be administered simultaneously by the infusion line.
Caution is recommended while administering oxaliplatin to patients with known hypersensitivity to other platinum agents.
Oxaliplatin is incompatible in solution with alkaline medications or media and hence it is advised that oxaliplatin should never be diluted with Sodium Chloride / Chloride containing infusion solutions.
Oxaliplatin has been found to be mutagenic in mammalian in vitro mutation chromosome test. Although carcinogenic studies have not been done. Oxaliplatin is considered probable carcinogen.
Oxaliplatin is embryotoxic in rats. Oxaliplatin may cause fetal harm when administered to pregnant women. The patient should be apprised of potential hazard to the fetus and potential risk for loss of the pregnancy if there is exposure to oxaliplatin during pregnancy.
It is not known whether oxaliplatin is excreted in human milk or not. Caution should be exercised when oxaliplatin is administered to a nursing woman as many drugs are excreted in human milk.
Inspect the solution visually for particulate matter and discolouration prior to administration.
Effects on ability to drive and use machine: Not known.
